PL378136A1 - Pirymidyny i triazyny hamujące replikacją wirusa HIV - Google Patents

Pirymidyny i triazyny hamujące replikacją wirusa HIV

Info

Publication number
PL378136A1
PL378136A1 PL378136A PL37813604A PL378136A1 PL 378136 A1 PL378136 A1 PL 378136A1 PL 378136 A PL378136 A PL 378136A PL 37813604 A PL37813604 A PL 37813604A PL 378136 A1 PL378136 A1 PL 378136A1
Authority
PL
Poland
Prior art keywords
hiv replication
triazines
replication inhibiting
inhibiting pyrimidines
pyrimidines
Prior art date
Application number
PL378136A
Other languages
English (en)
Other versions
PL227295B1 (pl
Inventor
Jerome Emile Georges Guillemont
Elisabeth Therese Jeanne Pasquier
Jan Heeres
Kurt Hertogs
Eva Bettens
Paulus Joannes Lewi
Jonge Marc Rene De
Lucien Maria Henricus Koymans
Frederik Frans Desire Daeyaert
Hendrik Maarten Vinkers
Paul Adriaan Jan Janssen
Original Assignee
Tibotec Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharmaceuticals Ltd. filed Critical Tibotec Pharmaceuticals Ltd.
Publication of PL378136A1 publication Critical patent/PL378136A1/pl
Publication of PL227295B1 publication Critical patent/PL227295B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Przedmiotem wynalazku są inhibitory replikacji wirusa HIV o wzorze (I), ich N-tlenki, ich sole addycyjne dopuszczone do stosowania w farmacji, ich czwartorzędowe związki aminowe oraz ich stereochemiczne postacie izomeryczne, ich zastosowanie w medycynie, sposoby ich wytwarzania oraz zawierające je kompozycje farmaceutyczne.
PL378136A 2003-02-20 2004-02-20 Pochodna pirymidyny hamujaca replikacje wirusa HIV PL227295B1 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP03100411.2 2003-02-20
EP03100411 2003-02-20
US47501203P 2003-06-02 2003-06-02
US60/475,012 2003-06-02
PCT/EP2004/050177 WO2004074262A1 (en) 2003-02-20 2004-02-20 Hiv replication inhibiting pyrimidines and triazines

Publications (2)

Publication Number Publication Date
PL378136A1 true PL378136A1 (pl) 2006-03-06
PL227295B1 PL227295B1 (pl) 2017-11-30

Family

ID=32910137

Family Applications (2)

Application Number Title Priority Date Filing Date
PL378064A PL226954B1 (pl) 2003-02-20 2004-02-20 Pochodna pirymidyny hamujaca replikacje wirusa HIV, kompozycja farmaceutyczna iprodukt jazawierajacy oraz sposób wytwarzania pochodnej pirymidyny
PL378136A PL227295B1 (pl) 2003-02-20 2004-02-20 Pochodna pirymidyny hamujaca replikacje wirusa HIV

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL378064A PL226954B1 (pl) 2003-02-20 2004-02-20 Pochodna pirymidyny hamujaca replikacje wirusa HIV, kompozycja farmaceutyczna iprodukt jazawierajacy oraz sposób wytwarzania pochodnej pirymidyny

Country Status (27)

Country Link
US (2) US7585870B2 (pl)
EP (2) EP1603887B1 (pl)
JP (2) JP4586014B2 (pl)
KR (2) KR20050094896A (pl)
CN (2) CN100572364C (pl)
AP (1) AP2005003373A0 (pl)
AR (2) AR044500A1 (pl)
AT (2) ATE506353T1 (pl)
AU (2) AU2004213186B2 (pl)
BR (2) BRPI0407741B8 (pl)
CA (2) CA2516699C (pl)
CL (2) CL2004000303A1 (pl)
CY (1) CY1106788T1 (pl)
DE (2) DE602004006383T2 (pl)
DK (1) DK1597238T3 (pl)
EA (2) EA011256B1 (pl)
ES (1) ES2287734T3 (pl)
HR (2) HRP20050821A2 (pl)
IL (2) IL169596A (pl)
MX (2) MXPA05008867A (pl)
MY (1) MY138308A (pl)
NO (2) NO20054311L (pl)
NZ (2) NZ541601A (pl)
PL (2) PL226954B1 (pl)
PT (1) PT1597238E (pl)
TW (2) TW200510339A (pl)
WO (2) WO2004074262A1 (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
BR0313059B8 (pt) 2002-07-29 2021-07-27 Rigel Pharmaceuticals composto, e, composição farmacêutica
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
CN102358738A (zh) 2003-07-30 2012-02-22 里格尔药品股份有限公司 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
US7456176B2 (en) 2004-04-08 2008-11-25 Targegen, Inc. Benzotriazine inhibitors of kinases
US7652051B2 (en) 2004-08-25 2010-01-26 Targegen, Inc. Heterocyclic compounds and methods of use
JP5095409B2 (ja) 2004-11-24 2012-12-12 ライジェル ファーマシューティカルズ， インコーポレイテッド スピロ２，４−ピリミジンジアミン化合物およびその使用
JP4801096B2 (ja) 2005-01-19 2011-10-26 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用
EP1904457B1 (en) 2005-06-08 2017-09-06 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US7528143B2 (en) 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
JP2009528295A (ja) 2006-02-24 2009-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
CN106045965A (zh) * 2006-12-29 2016-10-26 爱尔兰詹森科学公司 抑制hiv的5,6‑取代的嘧啶类化合物
US9006243B2 (en) * 2006-12-29 2015-04-14 Janssen R&D Ireland HIV inhibiting 6-substituted pyrimidines
EP2300013B2 (en) 2008-05-21 2024-11-13 Takeda Pharmaceutical Company Limited Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
TW201008933A (en) * 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
PE20110303A1 (es) 2008-09-11 2011-05-21 Pfizer Derivados de heteroaril acetamidas como activadores de glucoquinasa
AR074210A1 (es) * 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
ES2427279T3 (es) 2009-03-11 2013-10-29 Pfizer Inc. Derivados de benzofuranilo usados como inhibidores de glucocinasa
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
US9249124B2 (en) 2011-03-30 2016-02-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase inhibitors and methods of making and using thereof
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
GB201119358D0 (en) 2011-11-10 2011-12-21 Lewi Paulus J Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
GB201204756D0 (en) 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN110818690B (zh) * 2016-07-26 2021-08-10 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
CN106749203B (zh) * 2016-11-28 2020-04-10 洛阳聚慧医药科技有限公司 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用
EP3966206B1 (en) 2019-05-10 2023-08-09 Deciphera Pharmaceuticals, LLC Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
EP3966207B1 (en) 2019-05-10 2023-11-01 Deciphera Pharmaceuticals, LLC Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
JP7626722B2 (ja) 2019-06-17 2025-02-04 デシフェラ・ファーマシューティカルズ，エルエルシー アミノピリミジンアミドオートファジー阻害剤およびその使用方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US5691364A (en) * 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
HUP9900730A3 (en) 1995-11-23 2001-04-28 Janssen Pharmaceutica Nv Solid mixtures of cyclodextrins prepared via melt-extrusion
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
AU751573C (en) * 1998-03-27 2003-10-09 Janssen Pharmaceutica N.V. HIV inhibiting pyrimidine derivatives
EP0945447A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
JP3635238B2 (ja) * 1998-11-10 2005-04-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖの複製を阻害するピリミジン類
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
NZ513639A (en) 1999-04-15 2004-02-27 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
DE60025837T2 (de) * 1999-09-24 2006-11-02 Janssen Pharmaceutica N.V. Antivirale feste dispersionen
JP2003511378A (ja) * 1999-10-07 2003-03-25 アムジエン・インコーポレーテツド トリアジン系キナーゼ阻害薬
US7276510B2 (en) 2000-05-08 2007-10-02 Janssen Pharmaceutica, Inc. HIV replication inhibitors
WO2002036578A2 (en) * 2000-10-31 2002-05-10 Lynn Bonham Triazine derivatives as lpaat-b inhibitors and uses thereof
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7375222B2 (en) * 2002-02-05 2008-05-20 Astellas Pharma Inc. 2,4,6-Triamino-1,3,5-triazine derivative
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
EP1518855B1 (en) * 2002-06-28 2011-10-26 Astellas Pharma Inc. Diaminopyrimidinecarboxa mide derivative
BR0313059B8 (pt) * 2002-07-29 2021-07-27 Rigel Pharmaceuticals composto, e, composição farmacêutica
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.

Also Published As

Publication number Publication date
AR044499A1 (es) 2005-09-14
BRPI0407741B8 (pt) 2021-05-25
EP1603887A1 (en) 2005-12-14
AU2004213187A1 (en) 2004-09-02
IL169647A (en) 2013-05-30
ES2287734T3 (es) 2007-12-16
NO20054312L (no) 2005-11-16
NO20054311D0 (no) 2005-09-19
JP4586014B2 (ja) 2010-11-24
CL2004000303A1 (es) 2005-04-08
PL378064A1 (pl) 2006-02-20
NO20054312D0 (no) 2005-09-19
CN1751031A (zh) 2006-03-22
NO20054311L (no) 2005-10-27
WO2004074261A1 (en) 2004-09-02
IL169647A0 (en) 2007-07-04
AR044500A1 (es) 2005-09-14
WO2004074262A1 (en) 2004-09-02
ATE361915T1 (de) 2007-06-15
PL226954B1 (pl) 2017-10-31
DE602004006383T2 (de) 2008-01-10
CA2516699C (en) 2011-07-12
JP4586013B2 (ja) 2010-11-24
DK1597238T3 (da) 2007-09-10
MXPA05008866A (es) 2005-10-05
BRPI0407741B1 (pt) 2018-05-29
EP1597238B1 (en) 2007-05-09
MXPA05008867A (es) 2005-10-05
EA010423B1 (ru) 2008-08-29
AU2004213186A1 (en) 2004-09-02
CN1751030A (zh) 2006-03-22
AU2004213187B2 (en) 2009-11-05
KR20050094896A (ko) 2005-09-28
US7585870B2 (en) 2009-09-08
TW200500346A (en) 2005-01-01
CA2516589C (en) 2012-04-17
KR20050099994A (ko) 2005-10-17
ATE506353T1 (de) 2011-05-15
PL227295B1 (pl) 2017-11-30
CY1106788T1 (el) 2012-05-23
US20060142571A1 (en) 2006-06-29
JP2006518356A (ja) 2006-08-10
DE602004006383D1 (de) 2007-06-21
EP1603887B1 (en) 2011-04-20
HRP20050820A2 (en) 2006-11-30
AU2004213186B2 (en) 2009-10-01
EA200501327A1 (ru) 2006-02-24
IL169596A (en) 2017-02-28
CA2516699A1 (en) 2004-09-02
PT1597238E (pt) 2007-08-08
BRPI0407741A (pt) 2006-02-14
EA011256B1 (ru) 2009-02-27
IL169596A0 (en) 2007-07-04
NZ542428A (en) 2007-11-30
DE602004032321D1 (de) 2011-06-01
CN100572364C (zh) 2009-12-23
TW200510339A (en) 2005-03-16
CL2004000306A1 (es) 2005-04-08
CA2516589A1 (en) 2004-09-02
MY138308A (en) 2009-05-29
US20060194804A1 (en) 2006-08-31
JP2006518357A (ja) 2006-08-10
EP1597238A1 (en) 2005-11-23
CN1751031B (zh) 2010-07-21
US7442705B2 (en) 2008-10-28
NZ541601A (en) 2007-09-28
BRPI0407732A (pt) 2006-02-14
HRP20050821A2 (en) 2006-11-30
AP2005003373A0 (en) 2005-09-30
EA200501326A1 (ru) 2006-02-24

Similar Documents

Publication Publication Date Title
PL378064A1 (pl) Pirymidyny i triazyny hamujące replikację wirusa HIV
UA99617C2 (ru) Производные пирролконденсированного азотсодержащего гетероцикла, их получение и фармацевтическое применение
SE0202463D0 (sv) Novel compounds
PL378107A1 (pl) 1,2,4-triazyny hamujące HIV
MY141220A (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
NO20060001L (no) Nye P2X7-reseptorantagonister og deres anvendelse
BR0213562A (pt) Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
NO20085087L (no) Nye heterocykliske forbindelser
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
BRPI0606313A2 (pt) derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina, processo para sua preparação e seu uso em terapia
TNSN06411A1 (en) Pyrimidine urea derivatives as kinase inhibitors
MEP25908A (bs) Derivati pirazolo-hinazolina, postupci za njihovo dobijanje i njihova upotreba kao inhibitor kinaze
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
SE0400284D0 (sv) Novel compounds
UA83091C2 (en) Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
ZA200702645B (en) Diaminotriazole compounds useful as protein kinase inhibitors
BR0316950A (pt) Derivados de indazol como antagonistas de crf
GB0308201D0 (en) Novel compounds